Clinical Trial Update: A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating a triplet combination of pemetrexed, AB928 (etrumadenant), and AB122 (zimberelimab) in previously treated advanced or metastatic MTAP-d…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• Etrumadenant (etrumadenant)
• Pemetrexed (pemetrexed)
• Zimberelimab (zimberelimab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Urothelial Carcinoma, Metastatic Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING